Aspirin for the Prevention of Recurrent Venous Thromboembolism
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine whether aspirin is more effective than placebo for the prevention of recurrent
symptomatic venous thromboembolism when given for at least two years after the initial 6-12
month of oral anticoagulant therapy in patients with idiopathic venous thromboembolism